MRUS Merus N.V.

17.02
+0.12  (+1%)
Previous Close 16.9
Open 16.85
Price To Book 6.28
Market Cap 491,368,285
Shares 28,870,052
Volume 48,083
Short Ratio
Av. Daily Volume 111,219
Stock charts supplied by TradingView

NewsSee all news

  1. ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

  2. Merus Announces Chief Executive Officer Transition

    — Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 — UTRECHT, The Netherlands and

  3. Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage company developing innovative, full-length bispecific

  4. Merus Announces Pricing of Public Offering of Common Shares

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an

  5. Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2020 but does not plan to initiate a Phase 3 trial.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Phase 1/2 interim data due by end of 2020.
MCLA-128
Solid tumors - NRG1
Phase 1 readouts due 1H 2020.
MCLA-117
Acute Myeloid Leukemia
Phase 1 emerging data due YE 2019. Moved to 1Q 2020 due to no update.
MCLA-158
Colorectal cancer
Phase 1 dosing has commenced - May 9, 2019.
MCLA-145
Solid tumors

Latest News

  1. ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

  2. Merus Announces Chief Executive Officer Transition

    — Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 — UTRECHT, The Netherlands and

  3. Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage company developing innovative, full-length bispecific

  4. Merus Announces Pricing of Public Offering of Common Shares

    UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an

  5. Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed

  6. Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions

    Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

  7. Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage bispecific antibody company developing Biclonics®, innovative